- Home
- HTH vs ADMA Comparison
HTH vs ADMA Comparison
Compare HTH & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | ADMA |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2003 | 2012 |
Fundamental Metrics
Financial Performance| Metric | HTH | ADMA |
|---|---|---|
| Price | $37.43 | $10.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $37.50 | $25.67 |
| AVG Volume (30 Days) | 241.2K | ★ 9.5M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 51.72 | N/A |
| EPS | ★ 2.64 | 0.60 |
| Revenue | ★ $152,188,000.00 | $42,219,783.00 |
| Revenue This Year | N/A | $27.46 |
| Revenue Next Year | $3.22 | $22.11 |
| P/E Ratio | ★ $14.19 | $17.89 |
| Revenue Growth | 15.52 | ★ 43.85 |
| 52 Week Low | $28.43 | $7.21 |
| 52 Week High | $40.41 | $25.67 |
Technical Indicators
Market Signals| Indicator | HTH | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 55.92 | 44.86 |
| Support Level | $36.67 | $7.21 |
| Resistance Level | $38.30 | $16.61 |
| Average True Range (ATR) | 0.68 | 0.48 |
| MACD | 0.11 | 0.36 |
| Stochastic Oscillator | 69.63 | 82.81 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.